- Home
- LPX vs DNTH Comparison
LPX vs DNTH Comparison
Compare LPX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPX | DNTH |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LPX | DNTH |
|---|---|---|
| Price | $72.06 | $85.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $105.29 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.3M | 473.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,708,000,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.23 | $29.48 |
| P/E Ratio | $187.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $66.68 | $16.77 |
| 52 Week High | $102.86 | $96.50 |
Technical Indicators
Market Signals| Indicator | LPX | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 49.63 |
| Support Level | $69.28 | $82.00 |
| Resistance Level | $76.92 | $88.45 |
| Average True Range (ATR) | 2.82 | 4.46 |
| MACD | 0.13 | -0.85 |
| Stochastic Oscillator | 48.71 | 41.12 |
Price Performance
Historical ComparisonAbout LPX Louisiana-Pacific Corporation
Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.